ProMIS Neurosciences Inc. Common Shares (ON)
PMNProMIS Neurosciences Inc. is a biotechnology company focused on developing precision medicines for neurodegenerative diseases. Utilizing its proprietary platforms, the company researches and develops antibody-based therapies targeting misfolded proteins involved in conditions such as Alzheimer’s disease and other neurodegenerative disorders. Headquartered in Toronto, Ontario, ProMIS aims to advance treatments that can modify disease progression and improve patient outcomes.
Company News
ProMIS Neurosciences is implementing a one-for-twenty-five reverse stock split to address Nasdaq listing requirements and potentially increase its stock price, reducing outstanding shares from approximately 53.8 million to 2.15 million.
ProMIS Neurosciences secured $3 million in private financing through a PIPE offering, with an additional $9 million from warrant exercises, totaling approximately $12 million in gross proceeds to advance clinical development of PMN310 and support corporate operations.
The article discusses the growing pipeline of alpha-synuclein inhibitors, a class of investigational therapies targeting the aggregation of alpha-synuclein, a protein implicated in neurodegenerative diseases. The pipeline includes over 20 active players and 22+ pipeline therapies, with several promising candidates in various stages of clinical tr...
ProMIS Neurosciences announced positive top-line data from the first four cohorts of its Phase 1a clinical trial of PMN310, an antibody therapeutic targeting toxic misfolded proteins in Alzheimer's disease. The data showed a favorable safety profile, dose-dependent levels of PMN310 in the cerebrospinal fluid, and potential for target engagement i...
Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024 Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024
